Collectively, these results suggest that PXL770 treatment can have beneficial effects to ameliorate the proinflammatory phenotype of ALD diseased cells, in line with the well-known anti-inflammatory properties of AMPK activation. This evidence concerns the gene PRKAA1 and X-linked adrenoleukodystrophy.